KR20070118754A - Pharmaceutical composition for treating or preventing diabetes mellitus containing an extract of chinese herb as an effective ingredient - Google Patents
Pharmaceutical composition for treating or preventing diabetes mellitus containing an extract of chinese herb as an effective ingredient Download PDFInfo
- Publication number
- KR20070118754A KR20070118754A KR1020060052865A KR20060052865A KR20070118754A KR 20070118754 A KR20070118754 A KR 20070118754A KR 1020060052865 A KR1020060052865 A KR 1020060052865A KR 20060052865 A KR20060052865 A KR 20060052865A KR 20070118754 A KR20070118754 A KR 20070118754A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- extract
- diabetes
- herbal
- treating
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 239000000284 extract Substances 0.000 title abstract description 45
- 239000004615 ingredient Substances 0.000 title description 10
- 235000008434 ginseng Nutrition 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 7
- 239000012046 mixed solvent Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 37
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 25
- 239000012676 herbal extract Substances 0.000 claims description 23
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 18
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 18
- 229940010454 licorice Drugs 0.000 claims description 18
- 241000202807 Glycyrrhiza Species 0.000 claims description 17
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 16
- 240000000249 Morus alba Species 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 14
- 240000006079 Schisandra chinensis Species 0.000 claims description 14
- 241001061264 Astragalus Species 0.000 claims description 13
- 210000004233 talus Anatomy 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 241000167854 Bourreria succulenta Species 0.000 claims description 3
- 235000019693 cherries Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 241001632576 Hyacinthus Species 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 3
- 244000241838 Lycium barbarum Species 0.000 claims 3
- 244000170916 Paeonia officinalis Species 0.000 claims 3
- 240000004371 Panax ginseng Species 0.000 abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 16
- 239000008103 glucose Substances 0.000 abstract description 15
- 244000241872 Lycium chinense Species 0.000 abstract description 10
- 235000008216 herbs Nutrition 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 7
- 150000001720 carbohydrates Chemical class 0.000 abstract description 6
- 235000014633 carbohydrates Nutrition 0.000 abstract description 6
- 235000002789 Panax ginseng Nutrition 0.000 abstract description 5
- 241000045403 Astragalus propinquus Species 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 4
- 244000167222 Acanthopanax sessiliflorus Species 0.000 abstract description 3
- 235000017615 Acanthopanax sessiliflorus Nutrition 0.000 abstract description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract description 3
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract description 3
- 241000218213 Morus <angiosperm> Species 0.000 abstract description 3
- 241001625885 Polygonatum odoratum var. pluriflorum Species 0.000 abstract description 3
- 241001347459 Prunella vulgaris var. lilacina Species 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 3
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 241000405911 Rehmannia glutinosa Species 0.000 abstract description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract description 3
- 240000004534 Scutellaria baicalensis Species 0.000 abstract description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 abstract description 3
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 2
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 241000411851 herbal medicine Species 0.000 description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
- 229960001031 glucose Drugs 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 241000736199 Paeonia Species 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000018823 dietary intake Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 229940124595 oriental medicine Drugs 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 241000756042 Polygonatum Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 235000002566 Capsicum Nutrition 0.000 description 3
- 240000004160 Capsicum annuum Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- -1 Jinhae Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000006002 Pepper Substances 0.000 description 3
- 235000016761 Piper aduncum Nutrition 0.000 description 3
- 240000003889 Piper guineense Species 0.000 description 3
- 235000017804 Piper guineense Nutrition 0.000 description 3
- 235000008184 Piper nigrum Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000010440 gypsum Substances 0.000 description 3
- 229910052602 gypsum Inorganic materials 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 244000281702 Dioscorea villosa Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052571 earthenware Inorganic materials 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- BKNDOJUZMXDRDL-UHFFFAOYSA-N 4-butylcyclohexa-1,5-diene-1,4-diol Chemical compound CCCCC1(O)CC=C(O)C=C1 BKNDOJUZMXDRDL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 244000296796 Glycyrrhiza glabra var. glandulifera Species 0.000 description 1
- 241001279772 Glycyrrhiza pallidiflora Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 244000293610 Morus bombycis Species 0.000 description 1
- 241000301120 Morus lhou Species 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 244000270834 Myristica fragrans Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000695852 Polygonatum robustum Species 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000046342 Prorocentrum koreanum Species 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000010413 gardening Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930186755 gomisin Natural products 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910000898 sterling silver Inorganic materials 0.000 description 1
- 239000010934 sterling silver Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 α-글루코시다제(α-glucosidase)의 활성을 저해하는 효과를 나타낸 것이다.Figure 1 shows the effect of inhibiting the activity of α-glucosidase (α-glucosidase).
발명의 분야Field of invention
본 발명은 혈당강하 효과를 갖는 한약재 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes mellitus containing the herbal medicine extract having a hypoglycemic effect as an active ingredient.
배경기술Background
당뇨병은 췌장 세포에서 분비되는 인슐린의 분비 장애 및 작용 부족에 의해 유발된 대사장애로서, 포도당의 과잉생산, 체지방의 분해 및 단백질의 낭비를 수반 하고 글루카곤의 분비를 비정상적으로 항진시켜 대사상의 혼란을 야기시킨다 (Abrams, J.J., Ginsberg, H. et . al., Diabetes , 31:903, 1982).Diabetes is a metabolic disorder caused by dysfunction and lack of action of insulin secreted by pancreatic cells, which leads to overproduction of glucose, breakdown of body fat, and waste of protein, and abnormal glands of glucagon, causing metabolic confusion. (Abrams, JJ, Ginsberg, H. et . Al ., Diabetes , 31: 903, 1982).
진성 당뇨병(Diabetes mellitus)은 두 가지 유형으로 나누어지는데, 제 1 당뇨병(type 1 diabetes mellitus)은 혈액 내의 글루코스 조절 호르몬인 인슐린(Insulin)의 분비 결핍으로 야기되며, 주로 10대 내지 20대의 젊은 연령층에서 발병되기 때문에 소아당뇨병(juvenile diabetes)이라 불리기도 한다. 제 2 형 당뇨병(type 2 diabetes mellitus)은 주로 40대 이후에 발병되며, 우리나라 당뇨병 환자의 대부분을 차지한다. 제 1 형과는 달리 성인형 당뇨병이라 불리며 발병 원인은 아직 명확히 밝혀져 있지 않으나, 유전적인 요인과 환경적 요소가 함께 관여되어 발생하는 것으로 알려져 있다. 제 2 형 당뇨병의 병인으로 췌장 베타세포에서 인슐린 분비 장애와 표적세포에서 인슐린 작용의 결함(인슐린 저항성)이 모두 관찰된다. Diabetes mellitus is divided into two types. Type 1 diabetes mellitus is caused by a deficiency of insulin, a glucose-regulating hormone in the blood, mainly in young people in their teens to 20s. It is also called juvenile diabetes because it develops. Type 2 diabetes mellitus mainly occurs after the age of 40, and occupies most of the diabetic patients in Korea. Unlike type 1, it is called adult-type diabetes and the cause of the disease is not clear yet, but it is known to be caused by genetic factors and environmental factors. As a etiology of type 2 diabetes, both pancreatic beta cells secrete insulin secretion and target cells have a deficiency of insulin action (insulin resistance).
당뇨병 치료에 있어서 가장 중요한 목표는 혈당치를 가능한 정상치에 가깝게 조절하는 것인데, 공복혈당과 함께 식후 혈당조절이 당뇨병 증세의 개선과 합병증의 예방 또는 치료에 있어서 중요하며(Jenkins, D.J., Wolever, A. et . al., Starchy foods and glycemic index, Diabetes Care, 11:149, 1988; Menendez, C.M., Stoecker, B.J., The role of diet in improving glycemic control in Nutrition and Diabetes, Javanovic, L., Peterson, C.M.(ed.), Alan, R. Liss Inc., 15, 1995), 치료 방법으로는 약물요법, 식이요법 및 운동요법이 있다. The most important goal in the treatment of diabetes is to control blood glucose levels as close to normal as possible, and postprandial blood sugar control, together with fasting blood glucose, is important in improving diabetes and preventing or treating complications (Jenkins, DJ, Wolever, A. et. . al., Starchy foods and glycemic index , Diabetes Care , 11: 149, 1988; Menendez, CM, Stoecker, BJ, The role of diet in improving glycemic control in Nutrition and Diabetes , Javanovic, L., Peterson, CM (ed.), Alan, R. Liss Inc., 15, 1995), treatments include pharmacotherapy, diet and exercise.
현재 제 1 형 및 제 2 형 당뇨병 환자에게 사용되는 경구혈당강하제로는 α- 글리코시다제(α-glucosidase) 억제제, 설포닐우레아(sulfonylurea)제제 및 비구아니드(biguanide)제제가 있으며, α-글루코시다제 억제제는 섭취한 식이 중 탄수화물의 소화와 흡수를 지연시켜 식후 혈당 및 혈중 인슐린의 상승을 감소시킴으로써 당뇨병 치료 효과를 나타낸다. α-글루코시다제 저해제는 고인슐린혈증이나 저혈당을 유발하지 않고, 인슐린 분비를 촉진시키며 글루카곤 분비를 억제하는 글루카곤-유사-펩티드-1(glucagon-like peptide-1)의 소장에서의 분비를 촉진하는 장점을 가지고 있다 (Mooradian, A.D., Thurman, J.E., Drugs , 57:19, 1999; Baron, A.D. Diabetes Research and Clinical Practice, 40:S54, 1998). Oral hypoglycemic agents currently used in patients with type 1 and type 2 diabetes include α-glucosidase inhibitors, sulfonylureas, and biguanides. Glucosidase inhibitors have a therapeutic effect on diabetes by delaying the digestion and absorption of carbohydrates in the ingested diet, thereby reducing the elevation of postprandial blood sugar and blood insulin. α-glucosidase inhibitors promote the secretion of glucagon-like peptide-1 in the small intestine that promotes insulin secretion and inhibits glucagon secretion without causing hyperinsulinemia or hypoglycemia Has advantages (Mooradian, AD, Thurman, JE, Drugs , 57:19, 1999; Baron, AD Diabetes Research and Clinical Practice , 40: S 54, 1998).
현재 임상에서 사용하고 있는 것으로는 아카보스(acarbose), 보글리보스(voglibose) 및 미글리톨(miglitol) 등이 있으나, α-글리코시다제 저해제를 장기 복용한 경우 일부 환자에 있어서 복부 팽만감, 구토, 설사 등 부작용을 나타낼 수 있어 그 사용이 제한될 수 있다 (Hanefeld, M., Journal of Diabetes and its Complications, 12:228, 1998).The current clinical use includes acarbose, avoglibose and miglitol, but long-term use of α-glycosidase inhibitors may cause abdominal bloating, vomiting and diarrhea in some patients. May have adverse effects and may limit their use (Hanefeld, M., Journal of Diabetes and its Complications, 12: 228, 1998).
한약재의 혈당 저하효과에 관한 연구 결과는 다양하나, 특정 한약재의 혼합으로 제조된 한약재 조성물의 질병 예방 관련 연구결과는 미비한 실정이고, 현재까지 한약재 조성물의 효능으로 인해 출원된 것으로는 사상의학에 의한 체질별 주류 조성물 및 그 제조방법이 전부이다.Although there are various studies on the blood glucose lowering effect of medicinal herbs, studies on disease prevention of medicinal medicinal compositions prepared by mixing specific medicinal herbs are inadequate. Star liquor composition and its manufacturing method are all.
상기 한약재 조성물을 구성하는 주요 생약으로는 흰양삼(Panax ginseng C. A. Meyer), 황기(Astragalus membranaceus), 감초(Glycyrrhiza uralensis), 구기자(Lycium chinense), 뽕나무잎(Morus), 갈근(Pueraria thunbergiana), 하고 초(Prunella vulgaris var . lilacina), 오갈피(Acanthopanax sessiliflorus), 오미자(Schizandra chinensis), 황금(Scutellaria baicalensis), 산약(Dioscorea batatas), 황정(Polygonatum odoratum var . pluriflorum), 작약(Paeonia lactiflora), 생지(Rehmannia glutinosa)가 있다.The main herbal medicine constituting the herbal composition is white ginseng ( Panax ginseng C. A. Meyer ), Astragalus membranaceus ), licorice ( Glycyrrhiza uralensis ), wolfberry ( Lycium) chinense ), Morus leaves, Pueraria thunbergiana ), and second ( Prunella vulgaris var . lilacina ), Acanthopanax sessiliflorus ), Schizandra chinensis ), golden ( Scutellaria baicalensis ), medicinal herb ( Dioscorea batatas ), citrine ( Polygonatum odoratum var . pluriflorum ), peony ( Paeonia lactiflora ), dough ( Rehmannia glutinosa ).
흰양삼(Panax ginseng C. A . Meyer)은 인삼에 속하는 홍삼의 한 등급으로 뿌리는 약용하며 그 형태가 사람 형상이므로 인삼이라 한다. 인삼은 예로부터 불로·장생·익기(益氣)·경신(輕身)의 명약으로 일컬어진다. 한국에서 재배되는 인삼의 뿌리는 비대근(肥大根)으로 원뿌리와 2∼5개의 지근(支根)으로 되어 있고 미황백색이다. 지근의 수는 토질, 이식방법, 비료, 수분 등에 의해서 차이가 있으나, 분지성이 강한 식물이며 뿌리의 형태는 나이에 따라 차이가 있고 수확은 4∼6년근일때 한다. 한국 전매품인 홍삼의 원료로 쓰이는 것은 모두 6년근이다. 6년근의 동체는 길이 7∼10 ㎝, 지름 2.5 ㎝ 내외이고 뿌리 길이는 34 ㎝, 무게 80 g 정도이다. 인삼은 매년 땅속줄기에서 싹이 나오고 가을에는 줄기와 잎이 고사(枯死)하는데 고사한 줄기의 흔적이 남는다. White ginseng ( Panax ginseng C. A. Meyer ) is a grade of red ginseng belonging to ginseng. The root is medicinal and its shape is called human ginseng. Ginseng is said to be the old medicine of Buddha, Jangsaeng, Ikgi, and Shinshin. The root of ginseng cultivated in Korea is Geun-geun root (肥大 根), which consists of one root and two to five roots (支 根) and is pale yellow white. The number of roots is different depending on soil quality, transplantation method, fertilizer, water, etc., but it is a strong branching plant, and the shape of root varies according to age. Six years old is used as a raw material for red ginseng, a Korean monopoly. The six-year-old fuselage has a length of 7-10 cm, a diameter of 2.5 cm, and a root length of 34 cm and a weight of 80 g. Ginseng shoots come out from the underground stem every year, and in the fall, stems and leaves die, leaving traces of dead stems.
황기(Astragalus membranaceus)는 콩과로, 이뇨·소종 등의 효능이 있어 신체허약, 피로권태, 기혈허탈, 탈항, 자궁탈, 내장하수, 식은땀, 말초신경 등에 처방한다. 약초로서 재배하며 한방에서는 가을에 채취하여 노두와 잔뿌리를 제거하고 햇빛에 말린 것을 한약재의 황기라 한다. Astragalus membranaceus ( Astragalus membranaceus ) is a legume, diuretic, small-species, such as the effects of physical weakness, fatigue boredom, deprivation of blood, prolapse, uterine deprivation, visceral sewage, cold sweat, peripheral nerves. It is cultivated as an herb, and it is harvested in the fall of Korea to remove outcrops and roots, and dried in sunlight.
감초(Glycyrrhiza uralensis)의 꼬투리는 선처럼 가늘고 긴 모양으로 활처럼 굽으며 신장형의 종자가 6∼8개씩 들어 있다. 뿌리는 단맛이 나서 감미료, 한약재 로 사용한다. 시베리아산(G. glabra var . glandulifera), 에스파냐산(G. glabra) 등이 있으며 비슷한 종으로 개감초(G. pallidiflora)가 있다. 이는 단맛이 적고 감초와 달리 약용으로 쓰이지 않으며, 털이 적고 열매가 타원형이며 끝이 뾰족하고, 중국 동북부와 시베리아, 몽골 등지에 분포한다. Licorice ( Glycyrrhiza The pod of uralensis ) is thin and long like a line, curved like a bow, and contains 6 to 8 seeds. The roots are sweet and are used as sweeteners and herbal medicines. Siberian acid ( G. glabra var . glandulifera ) and G. glabra ( G. glabra ), and similar species is G. pallidiflora . It has little sweetness and is not used for medicinal purpose unlike licorice. It has little hair, fruit is oval, sharp in tip, and is distributed in northeastern China, Siberia and Mongolia.
구기자(Lycium chinense)는 구기자나무의 열매로 단백질, 지방, 당질, 칼슘, 인, 철분, 베타인, 루틴, 비타민(A, B1, B2, C) 등이 들어 있어 흡수가 빠르다. 한방에서는 강장제·해열제로 쓰고 간기능 보호 작용이 뛰어나 부작용이 별로 없다. 시력을 좋게 하고 당뇨병 등의 성인병을 예방하며 폐와 신장의 기능을 좋게 하고, 들기름과 섞어 숙성해 두었다가 머리에 바르면 흰머리가 생기는 것을 막아 주고 화상에도 효과가 있다고 알려져 있다. 수술 뒤나 회복기에 가루나 즙을 넣고 죽을 끓여 먹기도 하며 술을 담그기도 하는데, 허약체질을 보하는 강장제로 알려져 있다. 술을 조금 섞고 설탕을 넣어 잼을 만들기도 한다.Wolfberry ( Lycium chinense ) is the fruit of Goji berry, which contains protein, fat, sugar, calcium, phosphorus, iron, betaine, rutin, and vitamins (A, B1, B2, C). In oriental medicine, it is used as a tonic and antipyretic. It is known to improve eyesight, prevent adult diseases such as diabetes, improve the function of lungs and kidneys, and mix it with perilla oil, and then apply it to the hair to prevent the formation of gray hair and to burn. After the surgery or in the recovery period, put powder or juice, boil porridge, and soak alcohol. It is known as a tonic to weaken the constitution. A little alcohol is mixed with sugar to make jam.
뽕나무잎(Morus)은 쌍떡잎식물 쐐기풀목 뽕나무과 뽕나무속에 속한 낙엽교목 또는 관목의 총칭이며, 원산지는 온대·아열대 지방이며 세계에 30여 종이 있는데 한국에는 산상(山桑: M. bombycis), 백상(白桑: M. alba), 노상(魯桑: M. lhou)의 3종이 재배되고, 그 중에서 백상이 가장 많이 재배된다. 잎은 누에를 기르는 데 이용되며, 열매를 오디라고 하는데 술을 담그거나 날것으로 먹는다. 뿌리껍질은 한방에서 해열·진해·이뇨제·소종에 쓰고 목재는 가구재로 이용한다. Morus is a generic name for deciduous trees or shrubs belonging to the dicotyledonous nettle mulberry and mulberry, and its origin is temperate and subtropical, and there are about 30 species in the world. In Korea, M. bombycis and Baeksang (白)桑: M. alba), street (魯桑: 3 and paper cultivation of M. lhou), among Whites is grown most. Leaves are used to raise silkworms, and the fruit is called audi, which is dipped or eaten raw. Root bark is used for antipyretic, Jinhae, diuretic and sowing in oriental medicine, and wood is used for furniture.
갈근(Pueraria thunbergiana)은 칡뿌리의 껍질을 벗겨 잘게 썰어서 소금물 또는 백반수에 담갔다가 말린 것인데, 겉은 회백색의 섬유성이고 맛이 좀 쓰다. 성 분은 녹말이며 한방에서는 발한, 해열, 완하제(緩下劑)로서 고열, 두통, 고혈압, 심부전, 설사, 어깨가 결릴 때 등에 처방한다. 갈근탕은 감기약으로서 유명하다.Brown root ( Pueraria thunbergiana ) is peeled and finely chopped root roots, soaked in brine or white rice and dried. The outer surface is grayish white and tastes bitter. The starch is starch and herbal medicine for sweating, fever, and laxatives (緩 下 劑) as a high fever, headache, high blood pressure, heart failure, diarrhea, when the shoulder is prescribed. Galguntang is famous as a cold medicine.
하고초(Prunella vulgaris var . lilacina)는 길이 1.6 ㎜ 정도의 황갈색으로, 열매는 분과(分果: 분열과에서 갈라진 각 열매)이며, 봄에 어린 순을 식용한다. 생약 하고초는 꽃이삭을 말린 것이며, 한방에서는 임질, 결핵, 종기, 전신수종, 연주창에 약으로 쓰고 소염제·이뇨제로도 쓴다. 한국, 일본, 중국, 타이완, 사할린, 시베리아 남동부 등 한대에서 온대에 걸쳐 분포한다. 비슷한 종류로 흰색 꽃이 피는 것을 흰꿀풀(For . albiflora), 붉은 꽃이 피는 것을 붉은꿀풀(For . lilacina), 줄기가 밑에서부터 곧추서고 기는줄기가 없으며 짧은 새순이 줄기 밑에 달리는 것을 두메꿀풀(For. aleutica)이라고 한다. Prunella vulgaris var . lilacina ) is yellowish brown with a length of 1.6 mm. The fruit is a branch (divided in each branch) and edible young shoots in spring. The herbal medicinal herbs are dried flowers, and in Chinese medicine, gonorrhea, tuberculosis, boils, systemic edema, playing window and as anti-inflammatory and diuretic. It is distributed in temperate regions of Korea, Japan, China, Taiwan, Sakhalin, and southeastern Siberia. White Lamiaceae that a similar kind of blooming white flowers (For. Albiflora), red flower red Lamiaceae the blood (For. Lilacina), stems standing upright from the bottom there is no group stem dume that short sprouts running under the stem Lamiaceae (For aleutica ).
오갈피(Acanthopanax sessiliflorus)는 꽃이 8∼9월에 피고 자줏빛이며 작은꽃줄기가 짧고 꽃이 산형꽃차례에 밀생한다. 꽃잎은 5개, 암술대는 끝까지 합쳐진다. 열매는 핵과로 다소 편평한 타원형이며 10월에 검게 익는다. 뿌리껍질을 오갈피라고 하며 한방에서 강장제 및 진통제로 사용하고, 수피는 오갈피술을 만드는 데 쓰는 방향성 식물이다. 한국, 중국, 우수리, 아무르 등지에 분포한다. Acanthopanax sessiliflorus ) Flowers bloom in August-September, purplish, small flower stems are short, and flowers grow in inflorescences. The petals are five and the style is combined to the end. Fruits are nucleus, somewhat flat oval, ripening in October. Root bark is called Ogalpi, and it is used as a tonic and painkiller in oriental medicine, and bark is an aromatic plant used to make Ogalpisul. It is distributed in Korea, China, Ussuri, and Amur.
오미자(Schizandra chinensis)는 시잔드린, 고미신, 시트럴, 사과산, 시트르산 등의 성분이 들어 있어 심장을 강하게 하고 혈압을 내리며 면역력을 높여 주어 강장제로 쓴다. 폐 기능을 강하게 하고 진해·거담 작용이 있어서 기침이나 갈증 등을 치료하는 데 도움이 된다. 말린 열매를 찬물에 담가 붉게 우러난 물에 꿀, 설탕을 넣어 음료로 마시거나 화채나 녹말편을 만들어 먹는다. 밤, 대추, 미삼을 함 께 넣고 끓여 차를 만들거나 술을 담그기도 한다. Schizandra chinensis ) contains ingredients such as xanthrin, gomisin, citric acid, malic acid, citric acid, etc., which strengthen the heart, lower blood pressure, and increase immunity, which is used as a tonic. Strong lung function and antitussive, expectorant action to help treat coughs and thirst. Soak dried fruit in cold water, add honey and sugar to reddish water, drink it as a drink, or make a flower or starch. Boil chestnuts, jujube, and miso together to make tea or to soak alcohol.
황금(Scutellaria baicalensis)은 쌍떡잎식물 통화식물목 꿀풀과의 여러해살이풀로 4개의 수술 중 2개는 길고 암술은 1개이며 씨방은 4개로 깊게 갈라진다. 열매는 9월에 결실하며 둥근 모양으로 꽃받침 안에 들어 있다. 원뿌리는 원뿔형이고 살이 황색이다. 한방에서 뿌리를 해열·이뇨·지사·이담 및 소염제로 이용한다. 약용식물로 재배하며 한국, 중국, 몽골 및 시베리아 동부 등지에 분포한다.Golden ( Scutellaria baicalensis ) is a perennial herb of dicotyledon and calliflora nectar . Two of four stamens are long, one has pistil, and the ovary is deeply divided into four. Fruits are fruiting in September, rounded in calyx. The cone is conical and the flesh is yellow. In oriental medicine, roots are used as antipyretic, diuretic, branch, yedam and anti-inflammatory drugs. It is grown as a medicinal plant and is distributed in Korea, China, Mongolia, and eastern Siberia.
산약(Dioscorea batatas)은 마과(科: Disocoreaceae)에 속한 덩굴성 참마(Disocorea japonica) 또는 마(Disocorea batatas)의 덩이뿌리로 가을 상강 후부터 동지 사이에 채취하여 건조한 것으로, 외면은 백색 또는 황갈색을 띠고 내부는 분질 또는 호화된 각질로 단단하다. 성분은 전분, 점액질, 단백질, 지방, 아르기닌콜린 등과 디아스타제를 함유하고 있으며, 지라, 폐, 콩팥, 위, 간의 경락(經絡)에도 작용한다. 효능으로 식욕이 감퇴하며 원기가 부족할 때는 백출(白朮), 연밥, 인삼 등과 함께 달여 복용하며, 정액이 새거나 잠잘 때 식은땀을 흘릴 경우 숙지황, 산수유 등과 달여 복용한다. 몸이 마르고 원기가 부족한 경우 인삼, 패모, 복령, 행인 등을 배합하여 달여 복용하면 좋다고 알려져 있다. 당뇨병에도 매일 달여 장기간 차 대신 복용하면 효과가 있다고 알려져 있으나, 염증성 설사를 하거나 대변이 굳을 때는 복용을 중지한다.Yam (Dioscorea batatas) is magwa (科: Disocoreaceae) vine yam belongs to (Disocorea japonica ) or hemp ( Disocorea It is a tube root of batatas ), which is collected between autumn and winter seasons, and dried in winter. The outer surface is white or yellowish brown, and the inside is solid or powdered keratin. Ingredients contain starch, mucus, protein, fat, arginine choline and diastases, and act on the meridians, lungs, kidneys, stomach and liver. When the appetite is reduced and energy is insufficient, it is taken monthly with Baekchul, white rice, ginseng and so on. When the body is dry and lacking in energy, ginseng, femo, bokyeong, passersby, etc., is known to be a good combination. Even if you take diabetes every month for a long time instead of tea, it is known to be effective, but when you have inflammatory diarrhea or stool harden, stop taking it.
황정(Polygonatum odoratum var . pluriflorum)은 잎 뒷면에 유리조각 같은 돌기가 있고 꽃의 길이가 2∼2.5 ㎝인 것을 산둥굴레(Var . thunbergii), 잎 뒷면 맥 위에 잔 돌기가 많고 꽃이 1∼4개씩 달리는 것을 큰둥굴레(Var . maximowiczii), 잎은 길이 16 ㎝,나비 5 ㎝ 정도이고 꽃이 4개씩 달리는 것을 맥도둥굴레(P. koreanum), 전체가 크고 잎 뒷면에 털이 있으며 꽃이 2∼5개씩 달리는 것을 왕둥굴레(P. robustum)라고 한다. 봄철에 어린잎과 뿌리줄기를 식용한다. 생약의 위유는 뿌리줄기를 건조시킨 것이며, 한방에서는 뿌리줄기를 번갈, 당뇨병, 심장쇠약 등의 치료에 사용하며 한국, 일본, 중국에 분포한다.Hwangjeong (Polygonatum odoratum var . pluriflorum) is greater that the projections Polygonatum such a piece of glass and there are many mountains that the length of the flower 2~2.5 ㎝ Polygonatum (Var. thunbergii), turning over the leaves cup the back of the Mac running Flowers 1-4 on the back of each leaf (Var . maximowiczii), leaf length is 16 ㎝, butterfly about 5 ㎝ and are hairy on McDonagh Polygonatum (P. koreanum), the entire back of the leaves large flower that is run by one fourth king that Polygonatum each flower 2-5 run (P. robustum ). Eat young leaves and rhizomes in the spring. The crude oil of the herbal medicine is the dried root stem, and in oriental medicine, it is used for the treatment of alternating root stem, diabetes, and heart failure, and is distributed in Korea, Japan, and China.
작약(Paeonia lactiflora)은 꽃이 아름다워 원예용으로 쓴다. 뿌리는 진통, 복통, 월경통, 무월경, 토혈, 빈혈, 타박상 등의 약재로 쓰인다. 중국에서는 진(晉)과 명(明)시대에 이미 관상용으로 재배되어 그 재배 역사는 모란보다 오래되었다. 송(宋)을 거쳐 청(淸)시대에는 수십 종류의 품종이 기록되어 있다. 한국, 몽골, 동시베리아 등지에 분포하는 것으로 알려져 있다. Peeonia lactiflora ) is beautiful for flowers and is used for gardening. Root is used as a medicine such as pain, abdominal pain, dysmenorrhea, amenorrhea, hemostasis, anemia, bruises. In China, it was already cultivated for ornamental purposes during the Qin and Ming times, and its cultivation history is older than that of peonies. Dozens of varieties are recorded in the Qing Dynasty after the Song. It is known to be distributed in Korea, Mongolia and East Siberia.
생지(Rehmannia glutinosa)는 중국이 원산지이고 약용식물로 재배한다. 한방에서는 뿌리의 생것을 생지황, 건조시킨 것을 건지황, 쪄서 말린 것을 숙지황이라고 한다. 숙지황은 보혈제로 쓰이고 생리불순, 허약 체질, 어린이의 발육 부진, 치매, 조루증, 발기부전에 사용하며, 생지황은 허약 체질, 토혈, 코피, 자궁 출혈, 생리불순, 변비에 사용하고, 건지황은 열병 후에 생기는 갈증과 장기 내부의 열로 인한 소갈증에 효과가 있으며 토혈과 코피를 그치게 하는 것으로 알려져 있다 (브리태니커 온라인 백과사전).Dough ( Rehmannia glutinosa ) is native to China and is grown as a medicinal plant. In Chinese medicine, raw raw sulfur of raw roots, dried dried guernsey yellow, steamed dried sujijihwang is called. Sukjihwang is used as a blood donor, menstrual disorders, weak constitution, children's developmental insufficiency, dementia, premature ejaculation, erectile dysfunction, raw jizohwang is used for weak constitution, bleeding, nosebleed, uterine bleeding, menstrual irregularity, constipation It is effective for thirst and internal heat thirst and is known to stop hemorrhage and nosebleeds (Brittanicer Online Encyclopedia).
그러나, 실제로 상기한 문헌들 및 연구 보고에서 상기 한약재의 당뇨병에 대한 치료 효과는 전혀 보고된 바 없다.In fact, however, the therapeutic effects of the herbal medicines on diabetes have not been reported in the above-mentioned documents and research reports.
대한민국 등록특허 10-0052207에서는 갈근, 향부자, 상백피, 맥문동, 천문 동, 황련, 치자, 황금, 박하, 죽엽, 활석, 석고, 대황, 황백, 반하, 백삼, 감초, 육계, 괄루인, 진피, 지모, 한수석, 산사, 신곡, 지실, 당귀, 백작약, 숙지황, 백출, 황기, 백복령, 연자육, 산약, 육종용, 오미자, 망초, 지골피, 연교, 후박, 우슬, 자단향, 사상자, 비해, 구기자, 복분자, 맥아, 산수유, 목단피, 육두구, 소백피, 익지인, 목통, 백자인, 석곡, 천궁, 행인, 목과, 청피, 금은화, 황정, 토사자, 석창포 및 용안육을 함유하는 생약 유래 식이성 섬유와 약제학적으로 허용가능한 담체를 포함하는 것을 특징으로 하는 당뇨병 치료제에 대해 기재되어 있다. 또한, 대한민국 등록특허 10-0189513에는 맥문동, 지모, 숙지황, 복령, 백삼, 감초, 석고 및 사인을 함유하는 당뇨병 치료제에 대해 기재되어 있고, 대한민국 등록특허 제10-0486963에서는 심층수, 유기 게르마늄 및 통초, 비파엽, 과루, 동과인, 두권, 행인, 쌍지, 의인, 차전초, 활석, 산약, 생지, 지모, 생내금, 갈근, 천화분, 산수유, 석각, 지모, 사삼, 맥동, 택사, 오미자, 당삼, 석고, 복령, 천련, 황금, 천문동, 두충, 계내금, 동출, 갑판, 토사자, 원삼, 창출, 인삼, 기과, 하수오, 바옥죽, 여정자, 구기자, 지골피, 감초, 촌동, 흥매 등의 한약재 추출물을 포함하는 당뇨병 치료 및 예방에 효과적인 건강보조식품에 대해 기재되어 있으나, 이는 혈당 강하에 효과가 있다는 기재만 있을 뿐 α-글루코시다제의 활성을 억제함으로써 혈당 강하 효과를 나타낸다는 것은 기재되어 있지 않다. Republic of Korea Patent Registration 10-0052207 in the roots, yangbuja, Sangbaekpi, Mcmundong, astronomical dong, rhubarb, gardenia, golden, peppermint, bamboo leaf, talc, gypsum, rhubarb, yellow white, halved, white ginseng, licorice, broiler, walnut, dermis, jimo , Hansuseok, Sansa, Singok, Jisil, Angelica, Earl, Baekjihwang, Baekchul, Astragalus, Baekbokryeong, Yeonjak, Sanctuary, Breeding, Schisandra chinensis, Forget-me-not, Zhigolpi, Yeongwa, Hakja, Wooseol, Rosewood incense, Casualties, Compared to Gugijagi, Bokbunja, Malt Medicinal acceptable dietary fiber and pharmaceutically acceptable, containing cornus, bark, nutmeg, cattle white, ripe, wooden, white porcelain, stone, celestial, passerby, throat, green skin, sterling silver, yellow, earthenware, stone spear and longan It describes a therapeutic agent for diabetes characterized in that it comprises a carrier. In addition, Republic of Korea Patent No. 10-0189513 discloses a diabetic treatment containing Macmundong, Jimo, Sukjihwang, Bokryeong, White ginseng, licorice, gypsum and sine, and in the Republic of Korea Patent No. 10-0486963, deep water, organic germanium and tongs, Loquat leaf, fruit tree, fruit and vegetable, two books, pedestrian, twin, righteous, chajeoncho, talc, pesticide, raw material, hair growth, raw money, rooting, natural flower, cornus, stone carving, hair growth, samsam, pulsation, taxa, Schisandra chinensis, ginseng, gypsum Includes herbal extracts such as Bokyeong, Cheonnyeon, Golden, Astronomical dong, Toe Chung, Gyeenggeum, Dongnae, Deck, Earthenware, Wonsam, Creation, Ginseng, Roof Tile, Shouo, Baekjuk, Itinerary, Gugija, Jigolpi, Licorice, Chondong, Heungmae, etc. It is described as a dietary supplement that is effective in the treatment and prevention of diabetes mellitus, but it is only described that it is effective in lowering blood sugar, it is described that exhibits a hypoglycemic effect by inhibiting the activity of α-glucosidase Uh no.
이에 본 발명자들은 당뇨병의 예방 또는 치료에 효과가 있는 천연 추출물을 개발하고자 예의 노력한 결과, 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물이 당질대사교란으로 인한 당뇨병의 예방 또는 치료에 효과가 있음을 확인하고 본 발명을 완성하게 되었다.Therefore, the present inventors have made efforts to develop a natural extract effective in the prevention or treatment of diabetes, white ginseng, Astragalus, licorice, gojija, mulberry leaves, brown root, haechocho, Ogalpi, Schisandra chinensis, golden, medicinal herbs, yellow peony, peony And it was confirmed that the herbal medicine extract consisting of dough is effective in the prevention or treatment of diabetes mellitus due to metabolic disturbances and completed the present invention.
본 발명의 주된 목적은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학 조성물을 제공하는데 있다. The main object of the present invention is the prevention of diabetes containing herbal extracts consisting of white ginseng, Astragalus, licorice, goji berry, mulberry leaf, brown root, red pepper, ogalpi, Schisandra chinensis, golden herb, yellow herb, yellow cherries, peony and dough as an active ingredient To provide a pharmaceutical composition for treatment.
본 발명의 다른 목적은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 당뇨병의 예방 또는 치료용 한약재 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공하는데 있다.Another object of the present invention is a herbal medicine extract for the prevention or treatment of diabetes consisting of white ginseng, Astragalus, licorice, gojija, mulberry leaves, brown root, vinegar, ogalpi, Schisandra chinensis, golden, mountain, yellow, peony and dough. A dietary supplement comprising an acceptable food supplement additive is provided.
상기 목적을 달성하기 위하여, 본 발명은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention contains a Chinese herbal medicine extract consisting of white ginseng, Astragalus, licorice, goji berry, mulberry leaf, brown root, haechocho, ogalpi, Schisandra chinensis, golden, medicinal herb, yellow flower, peony and raw materials as an active ingredient It provides a pharmaceutical composition for the prevention or treatment of diabetes.
본 발명에 있어서, 상기 한약재 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출한 것을 특징으로 할 수 있고, 상기 약학 조성물은 흰 양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지의 구성비가 1 : 0.7 : 0.4 : 0.7 : 0.4 : 0.7 : 1.1 : 0.9 : 0.4 : 0.4 : 0.7 : 0.7 : 0.9 : 0.9(w/w)인 것을 특징으로 할 수 있으며, 조성물 총 중량에 대하여 한약재 추출물을 0.1 내지 50 중량%로 포함하는 것을 특징으로 할 수 있다.In the present invention, the herbal extract may be characterized in that extracted with water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof, the pharmaceutical composition is white ginseng, Astragalus, licorice, wolfberry, mulberry leaves, brown root, The composition ratios of Gochucho, Ogalpi, Schisandra chinensis, Golden, Potion, Yellow Crown, Peony and Dough are 1: 0.7: 0.4: 0.7: 0.4: 0.7: 1.1: 0.9: 0.4: 0.4: 0.7: 0.7: 0.9: 0.9 (w / w It may be characterized in that), it may be characterized in that it comprises 0.1 to 50% by weight of the herbal extracts relative to the total weight of the composition.
본 발명에 있어서, 상기 한약재 추출물은 α-글루코시다제(α-glucosidase)의 활성을 억제함으로써 혈당을 저하시키는 것을 특징으로 할 수 있다.In the present invention, the herbal extract may be characterized by reducing blood sugar by inhibiting the activity of α-glucosidase (α-glucosidase).
본 발명은 또한, 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 당뇨병의 예방 또는 치료용 한약재 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공한다.The present invention is also a herbal medicine extract for preventing or treating diabetes consisting of white ginseng, Astragalus, licorice, gojija, mulberry leaves, brown root, hyacinth, ogalpi, Schisandra chinensis, golden herb, yellow pepper, peony and peony and foodstuffs. It provides a dietary supplement comprising possible food supplement additives.
본 발명에 있어서, 상기 건강보조식품은 분말, 과립, 정제, 캡슐 또는 음료인 것을 특징으로 할 수 있다.In the present invention, the health supplement may be characterized in that the powder, granules, tablets, capsules or beverages.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 한약재 조성물은 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지를 동결 건조하여 마쇄한 후, 건조된 시료 중량의 약 2 내지 15배, 바람직하게는 약 5 내지 10배 부피의 물, 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C4의 저급 알콜 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매, 바람직하게는 메탄올로 실온에서 약 1시간 내지 1일, 바람직하게는 6시간 내지 12시간 동안 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출, 바람직하게는 열수 추출하고, 감압여과에 의해 추출액과 잔사를 분리한 다음, 상기 수득된 잔사에 추출 시작 당시의 한약재 조성물 시료 중량의 약 2 내지 10배, 바람직하게는 약 3 내지 5배 부피의 물, 메탄올, 에탄올, 부탄올 등과 같은 C1 내지 C4의 저급 알콜 또는 이들의 약 1:0.1 내지 1:10의 혼합비를 갖는 혼합용매, 바람직하게는 메탄올로 1 내지 10시간, 더욱 바람직하게는 1시간 내지 5시간 동안 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출, 바람직하게는 열수 추출한 후, 감압여과 및 농축하여 한약재 추출물을 수득할 수 있다.Herbal medicine composition of the present invention, white ginseng, Astragalus, licorice, gojija, mulberry leaf, brown root, gojicho, ogalpi, Schisandra chinensis, golden, cayenne, yellow, peony and dough to freeze-dried and milled, the weight of the dried sample weight 2 to 15 times, preferably about 5 to 10 times the volume of water, C 1 to C 4 lower alcohols such as methanol, ethanol, butanol and the like or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, Preferably hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction, preferably hot water extraction with methanol for about 1 hour to 1 day, preferably 6 hours to 12 hours at room temperature with methanol, and extract and residue After separating, the obtained residues of C 1 to C 4 such as about 2 to 10 times, preferably about 3 to 5 times the volume of water, methanol, ethanol, butanol, etc. A low egg Hot water extraction, cold extraction, reflux cooling extraction or sonication for 1 to 10 hours, more preferably 1 to 5 hours with kohl or a mixed solvent thereof having a mixing ratio of about 1: 0.1 to 1:10, preferably methanol After extraction, preferably hot water extraction, filtration and concentration under reduced pressure may be used to obtain a herbal extract.
본 발명의 추출물을 포함하는 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. Pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, or may be used alone or in combination with other pharmaceutically active compounds, as well as in any suitable collection.
본 발명에 따른 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리 톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. The pharmaceutical compositions according to the invention can be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., respectively, according to conventional methods. Can be. Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like are mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the extracts of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the preferred effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. The extract of the present invention can be administered to mammals such as mice, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명은 당뇨병의 예방 또는 치료 효과를 나타내는 상기 한약재 추출물 및 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 건강보조식품을 제공한다. 한약재 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류, 분말, 과립, 정제, 캡슐 및 음료 등이 있다.The present invention provides a dietary supplement comprising the herb extract and a foodstuff acceptable food supplement additive exhibiting a prophylactic or therapeutic effect of diabetes. Examples of foods to which the medicinal herb extract can be added include various foods, beverages, gums, teas, vitamin complexes, health functional foods, powders, granules, tablets, capsules and beverages.
또한, 당뇨병의 예방 또는 치료 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of preventing or treating diabetes. At this time, the amount of the extract in the food or beverage may be added in 0.01 to 15% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml. have.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술 한 천연 탄수화물의 예는 모노사카라이드, 포도당, 과당 등의 디사카라이드, 말토스, 슈크로스 등의 폴리사카라이드, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 레바우디오시드 A, 글리시르히진 등의 스테비아 추출물) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the extract as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include conventional sugars such as monosaccharides, disaccharides such as glucose and fructose, polysaccharides such as maltose and sucrose, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. to be. As flavoring agents other than those mentioned above, natural flavoring agents (stevia extracts such as taumartin, rebaudioside A, glycyrgin) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 한약재 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the herbal extracts of the present invention are various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the extract of the present invention may contain natural fruit juice and fruit flesh for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is usually selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
실시예 1. 한약재 추출물의 제조Example 1. Preparation of Herbal Extracts
시중에서 구입(구입처: (주)광명생약)한 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지를 각각 10 g, 7 g, 4 g, 7 g, 4 g, 7 g, 11 g, 9 g, 4 g, 4 g, 7 g, 7 g, 9 g, 9 g씩 섞어 동결건조한 후 마쇄하여 하기 실시예의 시료로 사용하였다. 한약재 조성물은 시료 중량의 10배에 해당하는 100% 메탄올을 첨가하여 12시간 동안 자석교반기를 이용하여 추출하였다. 감압 여과하여 추출액과 잔사를 분리한 다음, 얻어진 잔사에 추출 시작 당시의 한약재 조성물 중량의 5배에 해당하는 100% 메탄올을 첨가하여 6시간 동안 자석교반기를 이용하여 추출하였다. 다시 감압여과한 후, 얻어진 잔사에 추출 시작 당시의 한약재 조성물 중량의 3배에 해당하는 100% 메탄올을 첨가하여 3시간 동안 자석교반기를 이용하여 추출한 다음, 감압여과 및 농축하여 추출물을 수득하였다. Commercially purchased white ginseng, Astragalus, licorice, wolfberry, mulberry leaf, brown root, haechocho, ogalpi, schisandra chinensis, golden pepper, yellow pepper, yellow flower, peony and dough, respectively 10 g, 7 g , 4 g, 7 g, 4 g, 7 g, 11 g, 9 g, 4 g, 4 g, 7 g, 7 g, 9 g, 9 g each, lyophilized and ground to use as a sample of the following example . The herbal composition was extracted using a magnetic stirrer for 12 hours by adding 100% methanol corresponding to 10 times the sample weight. After filtering under reduced pressure to separate the extract and the residue, 100% methanol corresponding to 5 times the weight of the herbal composition at the start of extraction was added to the obtained residue, and extracted using a magnetic stirrer for 6 hours. After filtration under reduced pressure again, 100% methanol corresponding to three times the weight of the herbal composition at the start of extraction was added to the obtained residue, followed by extraction using a magnetic stirrer for 3 hours, followed by filtration under reduced pressure and concentration to obtain an extract.
실시예 2. 한약재 추출물의 α-글루코시다제 활성 저해 여부 측정Example 2. Determination of inhibition of α-glucosidase activity of herbal extracts
효모(yeast) α-글루코시다제(α-glucosidase)는 시그마사(Sigma, Louis, MO, USA)로부터 구매하여 사용하였으며, 효소기질은 피라노사이드(para-nitrophenyl-alpha-D-glucopyranoside)를 사용하였고, 양성대조구로는 혈당상승억제제로서 임상적으로 사용되고 있는 아카보스(acarbose, 바이엘-코리아)를 사용하 였다. 상기 실시예 1에서 수득한 한약재 추출물을 건조시킨 후, 디메틸설폭사이드(dimethylsulfoxide)에 0.5 ㎎/㎖의 농도로 용해시킨 다음, 이를 효모 α-글루코시다제를 함유한 효소반응액에 넣어 α-글루코시다제의 저해 정도를 측정하였다.Yeast α-glucosidase was purchased from Sigma, Louis, MO, USA, and the enzyme substrate was para-nitrophenyl-alpha-D-glucopyranoside. As a positive control, acarbose (acarbose, Bayer-Korea), which is used clinically, is used as a blood glucose increase inhibitor. After drying the medicinal herb extract obtained in Example 1, dissolved in dimethylsulfoxide (dimethylsulfoxide) at a concentration of 0.5 mg / ㎖, and put it in the enzyme reaction solution containing yeast α-glucosidase α-glucose The degree of inhibition of sidase was measured.
그 결과, 한약재 추출물 및 아카보스의 효소활성 저해효과는 각각 25.2%, 20.7%로, α-글루코시다제를 유의적으로 저해함을 확인할 수 있었다 (도 1).As a result, the enzymatic activity inhibitory effect of the herbal extract and acarbose was 25.2%, 20.7%, respectively, it was confirmed that significantly inhibited α-glucosidase (Fig. 1).
실시예 3. 제2형 당뇨 동물모델의 식이섭취량 및 체중 증가량 측정Example 3 Measurement of Dietary Intake and Weight Gain in Type 2 Diabetic Animal Models
상기 실시예 2에서 시험관내(In vitro) α-글루코시다제 활성 저해가 우수한 것으로 나타난 한약재 추출물의 생체내(In vivo) 당뇨병 개선효과를 측정하기 위해, 제 2형 당뇨동물 모델인 4주령의 db/db 마우스를 두 군의 평균혈당이 비슷하도록 난괴법으로 분리하여, 대조군에게는 기초식이를, 섭취군에게는 기초식이에 동결건조된 상기 한약재 추출물을 10% 함유한 식이를 6주 동안 섭취시켰다 (표 1). 식이와 식수는 자유롭게(ad libitum) 섭취할 수 있도록 하였으며, 사육실의 온도 및 습도는 각각 20~25℃, 50~60%로 유지하였고, 명암은 12시간 간격으로 점등 및 소등을 하였다. 동물 체중과 식이 섭취량은 일주일에 3회 측정하였다. In vitro ( In Example 2) vitro) in vivo (In the medicinal herb extracts shown to let the α- glucosidase inhibiting activity superior to measure vivo) diabetes improving effect, and the second type separated by on experimental method the diabetic animal model, the db / db mice of 4 weeks of age to be similar to the mean blood glucose of the groups, the base diet for the control group, fed groups for basic diet A diet containing 10% of the medicinal herb extract lyophilized was taken for 6 weeks (Table 1). Diet and drinking water freely ( ad libitum ), the temperature and humidity of the breeding room were maintained at 20 ~ 25 ℃, 50 ~ 60%, respectively, the contrast was turned on and off every 12 hours. Animal weight and dietary intake were measured three times a week.
식이 섭취 6주째 실험동물을 희생하였다. 실험동물은 희생하기 전 14시간 동안 절식시킨 후, 이산화탄소 가스로 질식시켜 EDTA(ethylene diamine tetra acetic acid)를 10 ㎎씩 넣은 주사기로 심장에서 채혈하였다. 혈액은 3,000 rpm에서 15분간 원심분리하여 혈장을 수집한 후 -70℃에서 보관하였다. 간 조직은 적출하여 -70℃에서 보관하였다.Animals were sacrificed at 6 weeks of diet. The animals were fasted for 14 hours before sacrifice, suffocated with carbon dioxide gas, and blood was collected from the heart with a syringe containing 10 mg of ethylene diamine tetra acetic acid (EDTA). Blood was collected by centrifugation at 3,000 rpm for 15 minutes to collect plasma and stored at -70 ° C. Liver tissue was extracted and stored at -70 ° C.
모든 결과는 평균± 표준편차로 나타내었으며, 대조군과 한약재 추출물 투여군 사이의 유의성 검정은 스튜던트 T-검정(Student's t-test)을 사용하여 실시하였다 (α = 0.05).All results were expressed as mean ± standard deviation, and the significance test between the control group and the herbal extract administration group was carried out using the Student's t-test (α = 0.05).
체중 및 식이 섭취량 측정결과, 대조군과 한약재 추출물 식이를 6주간 공급한 섭취군의 체중은 각각 40.4 ± 2.6 g, 39.5 ± 1.6 g 이었으며, 식이 섭취량은 대조군 및 한약재 추출물 섭취군이 각각 4.47 ± 0.62 g/일, 4.30 ± 0.60 g/일로 유의적인 차이를 나타내지는 않았다 (표 2).Body weight and dietary intake were measured to be 40.4 ± 2.6 g and 39.5 ± 1.6 g for the control group and the medicinal herb extract for 6 weeks. The dietary intake was 4.47 ± 0.62 g / Day, 4.30 ± 0.60 g / day showed no significant difference (Table 2).
실시예 4. 한약재 추출물의 혈당 농도에 미치는 영향 측정 Example 4. Determination of the Effect of Herbal Medicine Extracts on Blood Glucose Levels
공복시 혈장 중의 글루코스(glucose) 함량은 어세이 키트(assay kit, 시그마사, 미국)를 이용한 글루코스 옥시다아제(glucose oxidase) 효소법(Raabo, E., Terkildsen, T.C., On the enzymatic determination of blood glucose, Scand J Clin Lab Invest 12:402, 1960)으로 측정하였다.Glucose content in fasting plasma was measured by glucose oxidase enzyme assay (Raabo, E., Terkildsen, TC, On the enzymatic determination of blood glucose, Scand J using an assay kit (Sigma, USA). Clin lab Invest 12: 402, 1960).
그 결과, 한약재 추출물 섭취군의 경우 공복시 혈장 포도당의 농도가 442.5±36.0 ㎎/dL로써, 대조군(489.8±34.6 mg/dL)에 비해 유의적으로 낮게 나타났다(p<0.05, 표 3). 이는 본 발명의 한약재 추출물의 장기간 섭취는 공복혈당을 유의적으로 감소시킴으로써 당뇨증세 개선 또는 치료에 효과적이라는 것을 나타낸다. As a result, the concentration of fasting plasma glucose was 442.5 ± 36.0 mg / dL in the herbal extract intake group, which was significantly lower than the control group (489.8 ± 34.6 mg / dL) ( p <0.05, Table 3). This indicates that long-term intake of the herbal extract of the present invention is effective in improving or treating diabetes by significantly reducing fasting blood glucose.
실시예 5. 급성 독성실험Example 5. Acute Toxicity Test
6 주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트(rat)를 사용하여 급성 독성실험을 실시하였다. 각 그룹당 2마리씩의 동물에 상기 한약재 추출물을 100 ㎎/㎏의 용량으로 1회 경구투여 하였다. 한약재 추출물 투여 후 동물의 폐사 여부, 임상증상 및 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 강장기와 흉강 장기의 이상 여부를 관찰하였다.Acute toxicity experiments were performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals in each group were orally administered with the herbal extract at a dose of 100 mg / kg. After administration of the medicinal herb extract, the mortality, clinical symptoms, and weight changes of the animals were observed. Hematological and hematological examinations were performed.
그 결과, 한약재 추출물을 투여한 모든 동물에서 특기할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사 및 부검 소견 등에서도 독성변화는 관찰되지 않았다. 또한, 본 발명의 한약재 추출물은 랫트에서 각각 100 ㎎/㎏까지도 독성 변화를 나타내지 않았으며, 경구투여 최소치사량(LD50)은 100 ㎎/㎏이상인 안전한 물질로 판단되었다. As a result, no significant clinical symptoms or dead animals were noted in all the animals to which the medicinal herb extract was administered, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings. In addition, the herbal extract of the present invention did not show a toxic change even in rats up to 100 mg / kg, respectively, and the minimum lethal dose (LD50) was determined to be a safe substance of 100 mg / kg or more.
이하, 본 발명의 한약재 추출물을 포함하는 약학 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the formulation of the pharmaceutical composition comprising the herbal extract of the present invention will be described, but the present invention is not intended to limit it, but is intended to explain in detail only.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
한약재 추출물 20 ㎎Herbal Medicine Extract 20 mg
유당 100 ㎎Lactose 100 mg
탈크(Talc) 10 ㎎Talc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예 2. 정제의 제조Formulation Example 2 Preparation of Tablet
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
옥수수전분 100 ㎎Corn starch 100 mg
유당 100 ㎎Lactose 100 mg
스테아린산 마그네슘(Magnesium stearate) 2 ㎎2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예 3. 캅셀제의 제조Formulation Example 3 Preparation of Capsule
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
결정성 셀룰로오스 3 ㎎3 mg of crystalline cellulose
락토오스(lactose) 14.8 ㎎Lactose 14.8 mg
마그네슘 스테아레이트 0.2 ㎎Magnesium Stearate 0.2mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4 Preparation of Injection
한약재 추출물 10 ㎎Herbal Medicine Extract 10mg
만니톨(mannitol) 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎Sterile distilled water for injection 2974 mg
Na2HPO4·12H2O 26 ㎎ Na 2 HPO 4 · 12H 2 O 26 ㎎
통상의 주사제의 제조방법에 따라 1 앰플당(2 ㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예 5. 액제의 제조Formulation Example 5 Preparation of Liquid
한약재 추출물 20 ㎎Herbal Medicine Extract 20 mg
이성화당(isomerized sugar) 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음, 상기의 성분을 혼합한 후 정제수를 가하여 전체의 용량이 100 ㎖가 되도록 조절해서 갈색병에 충진하여 멸균시킴으로써 액제를 제조한다.By dissolving each component in purified water according to a conventional liquid preparation method, and adding a proper amount of lemon aroma, and then mixing the above components and adding purified water to adjust the total volume to 100 ㎖ by filling in a brown bottle and sterilizing Prepare a liquid formulation.
제제예 6. 건강 식품의 제조Formulation Example 6 Preparation of Healthy Food
한약재 추출물 1000 ㎎Chinese Herb Extract 1000mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎Vitamin C 10 mg
비오틴(biotin) 10 ㎍10 μg biotin
니코틴산아미드(nicotinic acid amide) 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산(folic acid) 50 ㎍50 μg folic acid
판토텐산 칼슘(pantothenic acid calcium) 0.5 ㎎Pantothenic acid calcium 0.5 mg
무기질 혼합물 적량Mineral mixture
황산제1철(ferrous sulfate) 1.75 ㎎Ferrous sulfate 1.75 mg
산화아연(zinc oxide) 0.82 ㎎Zinc oxide 0.82 mg
탄산마그네슘(magnesium carbonate) 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨(potassium phosphate monobasic) 15 ㎎Potassium phosphate monobasic 15 mg
제2인산칼슘(dicalcium phosphate) 55 ㎎Dicalcium phosphate 55 mg
구연산칼륨(potassium citrate) 90 ㎎Potassium citrate 90 mg
탄산칼슘(calcium carbonate) 100 ㎎Calcium carbonate 100 mg
염화마그네슘(magnesium chloride) 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고 통상의 방법에 따라 건강식품 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixtures is a composition suitable for health foods in a preferred embodiment, but the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method, and then granulated. It can be prepared and used in the manufacture of health foods according to conventional methods.
제제예 7. 건강 음료의 제조Formulation Example 7 Preparation of Healthy Drink
한약재 추출물 100 ㎎Medicinal Herb Extract 100mg
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g0.3 g of vitamin B2
물 적량Water quantity
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후 여과하여 이를 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. After mixing the above components according to the conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the health beverage of the present invention Used to prepare the composition.
상기 조성비는 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a composition suitable for the preferred beverage in the preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
이상 상세히 기술한 바와 같이, 본 발명에서는 흰양삼, 황기, 감초, 구기자, 뽕나무잎, 갈근, 하고초, 오갈피, 오미자, 황금, 산약, 황정, 작약 및 생지로 구성된 한약재 추출물이 α-글루코시다제 저해활성을 나타낼 뿐 아니라, 공복 혈당을 감소시킨다는 것을 밝혀내고, 상기 한약재 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학 조성물 및 건강보조식품을 제공하는 효과가 있다.As described in detail above, in the present invention, the herbal medicine extract composed of white ginseng, Astragalus, licorice, goji berry, mulberry leaf, brown root, red pepper, ogalpi, Schisandra chinensis, golden, medicinal herb, yellow cherries, peony and dough is α-glucosidase In addition to showing inhibitory activity, it has been found to reduce fasting blood sugar, and has an effect of providing a pharmaceutical composition and health supplement for preventing or treating diabetes containing the herbal extract as an active ingredient.
본 발명에 따른 한약재 추출물은 α-글루코시다제 저해활성을 나타내고, 식후 탄수화물의 소화 속도를 느리게 하여 혈중 포도당 농도의 급격한 상승을 억제하므로 당뇨병 예방 또는 치료용 의약품 및 건강보조식품으로 이용할 수 있다.The herbal extract according to the present invention exhibits α-glucosidase inhibitory activity and slows down the digestion rate of carbohydrates after meals, thereby suppressing a rapid rise in blood glucose levels, and thus can be used as a preventive or therapeutic drug for diabetes or as a dietary supplement.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다. The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060052865A KR100795976B1 (en) | 2006-06-13 | 2006-06-13 | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060052865A KR100795976B1 (en) | 2006-06-13 | 2006-06-13 | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070118754A true KR20070118754A (en) | 2007-12-18 |
KR100795976B1 KR100795976B1 (en) | 2008-01-21 |
Family
ID=39137294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060052865A KR100795976B1 (en) | 2006-06-13 | 2006-06-13 | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100795976B1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100923043B1 (en) * | 2008-01-03 | 2009-10-22 | (주)케이엠제약 | Blood pressure therapeutic agent for chinese medicine and manufacture method thereof |
CN102579585A (en) * | 2011-01-07 | 2012-07-18 | 北京北大维信生物科技有限公司 | Blood sugar lowering medicinal composition and application thereof |
CN102579674A (en) * | 2012-03-15 | 2012-07-18 | 郭世伟 | Chinese herba astragalus powder for curing diabetes mellitus |
KR101246689B1 (en) * | 2010-08-19 | 2013-03-26 | (주) 제이비케이자연의학연구소 | Antidiabetic composition comprising plants extract mixture |
US8586106B2 (en) | 2011-12-06 | 2013-11-19 | The Concentrate Manufacturing Company Of Ireland | Fatigue-relieving herbal extracts and beverages comprising the same |
CN103750482A (en) * | 2014-01-03 | 2014-04-30 | 江苏科技大学 | Blood glucose-reducing healthcare beverage containing angelica keiskei |
KR20200106347A (en) * | 2019-03-04 | 2020-09-14 | 김선대 | Rice production method for blood sugar down using natural ingredients |
US10894070B2 (en) | 2011-04-01 | 2021-01-19 | James Zhou | Drug compound for the control of blood glucose, blood lipids and weight |
CN118141108A (en) * | 2024-01-27 | 2024-06-07 | 广州唯纳大健康产业科技有限公司 | Mineral ion liquid and application thereof in preparation of products with diabetes treatment effect |
KR102686726B1 (en) * | 2023-08-07 | 2024-07-19 | 송창규 | Herbal medicine composition for reducing postprandial blood sugar |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101090319B1 (en) | 2009-03-27 | 2011-12-07 | 유 선 정 | A composition having an effect of curing and preventing diabetes mellitus |
KR101062670B1 (en) | 2009-06-01 | 2011-09-06 | (주)아모레퍼시픽 | Composition for the prevention or treatment of obesity-related diseases mediated by the activation of AMPK containing 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan as an active ingredient |
KR101387695B1 (en) * | 2012-05-10 | 2014-04-21 | 주식회사 파낙스코리아 | The anti-diabetic composition mainly containing extracts of kudzu root, Solomon's seal and E. senticosus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010084486A (en) * | 2000-02-25 | 2001-09-06 | 정두순 | Method of manufacturing herbal medicine for lowering hypoglycemic treatment of diabetes |
KR100513068B1 (en) * | 2003-02-19 | 2005-09-07 | 주식회사 피케이엘 | Method for Correcting Line-width Variation by Stage Tilt |
KR100524146B1 (en) * | 2003-07-08 | 2005-10-26 | 주식회사태준제약 | New process for preparing Iodixanol |
-
2006
- 2006-06-13 KR KR1020060052865A patent/KR100795976B1/en not_active IP Right Cessation
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100923043B1 (en) * | 2008-01-03 | 2009-10-22 | (주)케이엠제약 | Blood pressure therapeutic agent for chinese medicine and manufacture method thereof |
KR101246689B1 (en) * | 2010-08-19 | 2013-03-26 | (주) 제이비케이자연의학연구소 | Antidiabetic composition comprising plants extract mixture |
CN102579585A (en) * | 2011-01-07 | 2012-07-18 | 北京北大维信生物科技有限公司 | Blood sugar lowering medicinal composition and application thereof |
US10894070B2 (en) | 2011-04-01 | 2021-01-19 | James Zhou | Drug compound for the control of blood glucose, blood lipids and weight |
US8586106B2 (en) | 2011-12-06 | 2013-11-19 | The Concentrate Manufacturing Company Of Ireland | Fatigue-relieving herbal extracts and beverages comprising the same |
CN102579674A (en) * | 2012-03-15 | 2012-07-18 | 郭世伟 | Chinese herba astragalus powder for curing diabetes mellitus |
CN103750482A (en) * | 2014-01-03 | 2014-04-30 | 江苏科技大学 | Blood glucose-reducing healthcare beverage containing angelica keiskei |
KR20200106347A (en) * | 2019-03-04 | 2020-09-14 | 김선대 | Rice production method for blood sugar down using natural ingredients |
KR102686726B1 (en) * | 2023-08-07 | 2024-07-19 | 송창규 | Herbal medicine composition for reducing postprandial blood sugar |
CN118141108A (en) * | 2024-01-27 | 2024-06-07 | 广州唯纳大健康产业科技有限公司 | Mineral ion liquid and application thereof in preparation of products with diabetes treatment effect |
Also Published As
Publication number | Publication date |
---|---|
KR100795976B1 (en) | 2008-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100795976B1 (en) | Pharmaceutical Composition for Treating or Preventing Diabetes Mellitus Containing an Extract of Chinese Herb as an Effective Ingredient | |
KR100793204B1 (en) | Pharmaceutical Composition for Treating or Preventing Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR101328668B1 (en) | Compositon with anti-obesity and anti-diabetic activity comprising cudrania tricuspidata and adlay, and use thereof | |
KR20160087112A (en) | Flower tea and method for manufacturing therof | |
KR20110056905A (en) | Composition of mixed herb medicine for leached tea | |
KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
KR100793205B1 (en) | Health Supporting Foods for Improving Coronary Heart Diseases or Arteriosclerosis Containing an Extract of Chinese Herb as an Effective Ingredient | |
KR101140325B1 (en) | Composition of mixed herb medicine for leached tea | |
KR101166883B1 (en) | Composition of mixed herb medicine for leached tea | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR20110056908A (en) | Composition of mixed herb medicine for leached tea | |
CN105795053A (en) | Health tea containing pyracantha fortuneana and preparation method of health tea | |
KR101795261B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Treatmenting and Protecting the Insomniac and the Method of Making the Same | |
KR102491108B1 (en) | Manufacturing process for rice syrup by using red ginseng and red ginseng rice syrup thereby the same that | |
KR20070025342A (en) | Poultry egg having function to promote secretion of insulin and method for producing the same | |
KR20010039199A (en) | A health drink and its manufacturing process | |
KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
KR100543405B1 (en) | Composition comprising the extract of Allium victorialis L. var. platyphyllum for treating or preventing diabetes mellitus | |
KR100865900B1 (en) | Composition comprising an extract of herbal combination(occ-i) or the powder(occ-ii) thereof for preventing and treating diabetes mellitus | |
KR100846521B1 (en) | Composition comprising an extract of herbal combination(oca-i) or the powder(oca-ii) thereof for preventing and treating diabetes mellitus | |
KR100758267B1 (en) | Compositions effective for removing hangover, which contain natural plant extracts | |
KR20080056927A (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121213 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131205 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |